We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PwC Report Highlights Skepticism Among Drugmakers Over User Fees
PwC Report Highlights Skepticism Among Drugmakers Over User Fees
December 7, 2010
As the FDA continues its push to adopt user fees for generic-drug makers, a new survey is highlighting drugmakers’ skepticism of the fees’ effectiveness and reinforcing calls for more frequent communication with the agency.